Study of Fecalibacteria prausntzii in Egyptian patients with inflammatory bowel disease.

IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY

Przegla̜d Gastroenterologiczny Pub Date : 2024-01-01 Epub Date: 2024-05-09 DOI:10.5114/pg.2024.139427

Khaled Abd El Atty, Hanan Nouh, Shwikar Abdelsalam, Ahmed Ellakany, Hany Abdaalah, Doaa Header

{"title":"Study of Fecalibacteria prausntzii in Egyptian patients with inflammatory bowel disease.","authors":"Khaled Abd El Atty, Hanan Nouh, Shwikar Abdelsalam, Ahmed Ellakany, Hany Abdaalah, Doaa Header","doi":"10.5114/pg.2024.139427","DOIUrl":null,"url":null,"abstract":"Introduction: Inflammatory bowel diseases (IBD) are characterised by chronic inflammation of the gastrointestinal tract. There aetiopathogenesis has not yet been fully elucidated. Faecalibacterium prausnitzii is one of the most abundant in human gut, and it is found in about 5% of the gut microbiota.Aim: To study the role of F. prausnitzii in Egyptian patients with ulcerative colitis (UC) and Crohn's disease (CD) and to assess its relationship with the disease activity.Material and methods: This study includes 80 patients divided as follows: group I: 30 patients with UC; group II: 30 patients with CD; and group III: 20 healthy patients as control. DNA execration was performed using a faecal extraction kit and quantitative SYBR green real time PCR to identify the core of F. prausnitzii.Results: In group 1 of UC patients, the level of bacteria was reduced by a mean of 1.68E-01, and in the control group by a mean of 2.72E-01 (p 2 = 0.004, significant). Regarding F. prausnitzii in UC patients according to Mayo score, in severe patients the level of bacteria was reduced significantly by a median of 4.80E-02. Regarding F. prausnitzii in group 2 of CD, the level of bacteria was significantly reduced by mean of 1.70E-01, and in the control group by a mean of 2.72E-01 (p 3 = 0.037, significant).Conclusions: There was a significant difference between CD and UC patients and the control group in F. prausnitzii. There was a significant reduction in the level of F. prausnitzii in severe UC cases.","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 2","pages":"151-158"},"PeriodicalIF":1.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200077/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Przegla̜d Gastroenterologiczny","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pg.2024.139427","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Inflammatory bowel diseases (IBD) are characterised by chronic inflammation of the gastrointestinal tract. There aetiopathogenesis has not yet been fully elucidated. Faecalibacterium prausnitzii is one of the most abundant in human gut, and it is found in about 5% of the gut microbiota.

Aim: To study the role of F. prausnitzii in Egyptian patients with ulcerative colitis (UC) and Crohn's disease (CD) and to assess its relationship with the disease activity.

Material and methods: This study includes 80 patients divided as follows: group I: 30 patients with UC; group II: 30 patients with CD; and group III: 20 healthy patients as control. DNA execration was performed using a faecal extraction kit and quantitative SYBR green real time PCR to identify the core of F. prausnitzii.

Results: In group 1 of UC patients, the level of bacteria was reduced by a mean of 1.68E-01, and in the control group by a mean of 2.72E-01 (p ₂ = 0.004, significant). Regarding F. prausnitzii in UC patients according to Mayo score, in severe patients the level of bacteria was reduced significantly by a median of 4.80E-02. Regarding F. prausnitzii in group 2 of CD, the level of bacteria was significantly reduced by mean of 1.70E-01, and in the control group by a mean of 2.72E-01 (p ₃ = 0.037, significant).

Conclusions: There was a significant difference between CD and UC patients and the control group in F. prausnitzii. There was a significant reduction in the level of F. prausnitzii in severe UC cases.

查看原文本刊更多论文

埃及炎症性肠病患者的粪便细菌研究。

导言炎症性肠病（IBD）以胃肠道慢性炎症为特征。其发病机制尚未完全阐明。目的：研究F. prausnitzii在埃及溃疡性结肠炎（UC）和克罗恩病（CD）患者中的作用，并评估其与疾病活动的关系：本研究包括 80 名患者，分为以下几组：第一组：30 名 UC 患者；第二组：30 名 CD 患者；第三组：20 名健康患者作为对照。使用粪便提取试剂盒进行DNA提取，并进行SYBR绿实时定量PCR检测，以确定F. prausnitzii的核心：结果：在第 1 组 UC 患者中，细菌数量平均减少了 1.68E-01，而在对照组中平均减少了 2.72E-01（P 2 = 0.004，显著）。至于根据梅奥评分计算的 UC 患者体内的 F. prausnitzii，重症患者的细菌水平显著降低，中位数为 4.80E-02。关于 CD 第 2 组的 F. prausnitzii，细菌水平显著降低，平均降低了 1.70E-01，而对照组的细菌水平显著降低，平均降低了 2.72E-01（p 3 = 0.037，显著）：结论：CD 和 UC 患者与对照组的 F. prausnitzii 存在明显差异。严重的 UC 病例中的 F. prausnitzii 水平明显下降。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Przegla̜d Gastroenterologiczny GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

2.20

自引率

7.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Gastroenterology Review is a journal published each 2 months, aimed at gastroenterologists and general practitioners. Published under the patronage of Consultant in Gastroenterology and Polish Pancreatic Club.